- Liedeke Koops, visiting research associate,
- Richard I Lindley (richard.lindley{at}ed.ac.uk), part time senior lecturer
- Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU
- Correspondence to: R I Lindley
- Accepted 4 April 2002
Abstract
Objectives: To determine whether consumer involvement would help to solve some of the ethical problems associated with research into thrombolysis for acute ischaemic stroke, with its inherent risk of fatal intracranial haemorrhage.
Design: Quantitative and qualitative research.
Setting and participants: Consultation phase: three meetings were held to discuss the planned research, and participants completed a questionnaire. Qualitative work: focus group meetings explored the issues raised during the consultation phase. Design of information leaflets for patients and relatives: trial materials were drafted during the consultation phase and revised in the light of feedback from the focus group meetings and review by patients and carers on a stroke rehabilitation unit.
Results: 54 people attended the consultation meetings. Four (9%) participants considered the risks of thrombolysis too great, but most (89%) were prepared to accept the treatment in a clinical trial. Nearly all would accept treatment if it was shown to be effective. Most (85%) would give their consent to enter the planned trial. The focus group meetings and feedback from patients and carers led to significant changes in the information leaflets. The revised trial materials were considered ethical by a national multicentre research ethics committee.
Conclusions: Consumers generally supported a planned trial, and their involvement helped to refine trial consent procedures and led to an ethically acceptable trial design.
Footnotes
-
Funding Boehringer Ingelheim provided an unrestricted educational grant to support this work but had no part in the design, conduct, analysis, or reporting of the study.
-
Competing interests RIL has accepted honoraria for lectures at satellite symposia sponsored by Boehringer Ingelheim and is supported in attending stroke conferences by Boehringer Ingelheim for his role as editor of Stroke Matters (1997 to present). Boehringer Ingelheim holds the European licence for alteplase, a thrombolytic agent, and has donated a supply of alteplase and placebo for the third international stroke trial, an independent trial evaluating alteplase for acute ischaemic stroke, of which RIL is the principal investigator.

Patient information sheet on bmj.com
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Mendeley
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Re: Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001-10
Published 16 May 2012
Re: Outcomes of elective induction of labour compared with expectant management: population based study
Published 16 May 2012
Re: Outcomes of elective induction of labour compared with expectant management: population based study
Published 16 May 2012
Re: Why the US healthcare system is failing, and what might rescue it
Published 16 May 2012
Re: Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis
Published 16 May 2012
Most responses
Is spending on proton beam therapy for cancer going too far, too fast? (11 responses)
Published 17 Apr 2012 - 23:32
What are the benefits of an early diagnosis? (8 responses)
Published 18 Apr 2012
The psychiatric oligarchs who medicalise normality (8 responses)
Published 2 May 2012
Are doctors justified in taking industrial action in defence of their pensions? No (8 responses)
Published 8 May 2012 - 12:21
Are doctors justified in taking industrial action in defence of their pensions? Yes (8 responses)
Published 8 May 2012 - 12:21